Vitrolife AB (publ) Interim report Q1, 2025: Strong performance in EMEA
Vitrolife reported Q1 2025 financial results showing mixed regional performance. Sales reached SEK 842 million, representing a 1% increase in local currencies and flat growth in SEK. Excluding discontinued business, growth was 3%. Regional performance varied significantly with EMEA showing strong growth of 8% (14% excluding discontinued business), Americas growing 9%, while APAC declined 15%.
By product category, excluding discontinued business, Consumables grew 6%, while Technologies declined 5% and Genetics increased 4%. The company's gross margin improved slightly to 57.4% from 57.1%. EBITDA decreased to SEK 257 million with a margin of 30.6%, impacted by a negative foreign exchange effect of SEK 13 million. Operating cash flow was SEK 69 million, and net income reached SEK 100 million, resulting in earnings per share of SEK 0.74.
Vitrolife ha comunicato i risultati finanziari del primo trimestre 2025 mostrando performance regionali contrastanti. Le vendite hanno raggiunto 842 milioni di SEK, con un aumento dell'1% a valute locali e una crescita stabile in SEK. Escludendo le attività cessate, la crescita è stata del 3%. La performance regionale ha mostrato variazioni significative: forte crescita dell'8% in EMEA (14% escludendo le attività cessate), aumento del 9% nelle Americhe, mentre l'APAC ha registrato un calo del 15%.
Per categoria di prodotto, al netto delle attività cessate, i Consumabili sono cresciuti del 6%, mentre le Tecnologie sono diminuite del 5% e la Genetica è aumentata del 4%. Il margine lordo dell'azienda è migliorato leggermente, passando dal 57,1% al 57,4%. L'EBITDA è sceso a 257 milioni di SEK con un margine del 30,6%, influenzato da un effetto negativo sul cambio pari a 13 milioni di SEK. Il flusso di cassa operativo è stato di 69 milioni di SEK, mentre l'utile netto ha raggiunto i 100 milioni di SEK, con un utile per azione di 0,74 SEK.
Vitrolife presentó los resultados financieros del primer trimestre de 2025 mostrando un desempeño regional mixto. Las ventas alcanzaron los 842 millones de SEK, lo que representa un aumento del 1% en monedas locales y un crecimiento estable en SEK. Excluyendo negocios discontinuados, el crecimiento fue del 3%. El desempeño regional varió significativamente: EMEA mostró un fuerte crecimiento del 8% (14% excluyendo negocios discontinuados), América creció un 9%, mientras que APAC disminuyó un 15%.
Por categoría de producto, excluyendo negocios discontinuados, los Consumibles crecieron un 6%, mientras que las Tecnologías disminuyeron un 5% y la Genética aumentó un 4%. El margen bruto de la compañía mejoró ligeramente, pasando del 57,1% al 57,4%. El EBITDA disminuyó a 257 millones de SEK con un margen del 30,6%, afectado por un efecto negativo de tipo de cambio de 13 millones de SEK. El flujo de caja operativo fue de 69 millones de SEK y el ingreso neto alcanzó los 100 millones de SEK, resultando en ganancias por acción de 0,74 SEK.
Vitrolife는 2025년 1분기 재무 실적을 발표하며 지역별 성과가 엇갈렸습니다. 매출은 8억 4,200만 SEK로 현지 통화 기준 1% 증가했으며 SEK 기준으로는 변동이 없었습니다. 중단된 사업을 제외하면 성장률은 3%였습니다. 지역별 성과는 크게 달랐는데, EMEA 지역은 8% 성장(중단 사업 제외 시 14%), 미주 지역은 9% 성장했으나 APAC 지역은 15% 감소했습니다.
제품 카테고리별로는 중단 사업 제외 시 소모품이 6% 성장했고, 기술은 5% 감소했으며, 유전학은 4% 증가했습니다. 회사의 총이익률은 57.1%에서 57.4%로 소폭 개선되었습니다. EBITDA는 2억 5,700만 SEK로 감소했으며, 마진은 30.6%였고, 1,300만 SEK의 환율 부정적 영향이 있었습니다. 영업 현금 흐름은 6,900만 SEK였고, 순이익은 1억 SEK에 달해 주당순이익은 0.74 SEK였습니다.
Vitrolife a publié ses résultats financiers du premier trimestre 2025, montrant des performances régionales contrastées. Les ventes ont atteint 842 millions de SEK, soit une augmentation de 1 % en devises locales et une croissance stable en SEK. En excluant les activités abandonnées, la croissance a été de 3 %. La performance régionale a varié significativement : forte croissance de 8 % en EMEA (14 % hors activités abandonnées), croissance de 9 % en Amériques, tandis que l’APAC a reculé de 15 %.
Par catégorie de produit, hors activités abandonnées, les Consommables ont progressé de 6 %, les Technologies ont diminué de 5 % et la Génétique a augmenté de 4 %. La marge brute de l’entreprise s’est légèrement améliorée, passant de 57,1 % à 57,4 %. L’EBITDA a diminué à 257 millions de SEK avec une marge de 30,6 %, impacté par un effet de change négatif de 13 millions de SEK. La trésorerie opérationnelle s’est élevée à 69 millions de SEK, et le résultat net a atteint 100 millions de SEK, soit un bénéfice par action de 0,74 SEK.
Vitrolife meldete die Finanzergebnisse für das erste Quartal 2025 mit gemischter regionaler Performance. Der Umsatz erreichte 842 Millionen SEK, was einem Anstieg von 1 % in lokalen Währungen und einem stabilen Wachstum in SEK entspricht. Ohne Berücksichtigung eingestellter Geschäftsbereiche betrug das Wachstum 3 %. Die regionale Performance variierte deutlich: EMEA verzeichnete ein starkes Wachstum von 8 % (14 % ohne eingestellte Geschäftsbereiche), Amerika wuchs um 9 %, während APAC um 15 % zurückging.
Nach Produktkategorie wuchsen ohne eingestellte Geschäftsbereiche die Verbrauchsmaterialien um 6 %, die Technologien sanken um 5 % und die Genetik stieg um 4 %. Die Bruttomarge des Unternehmens verbesserte sich leicht von 57,1 % auf 57,4 %. Das EBITDA sank auf 257 Millionen SEK bei einer Marge von 30,6 %, beeinflusst durch einen negativen Währungseffekt von 13 Millionen SEK. Der operative Cashflow betrug 69 Millionen SEK, und der Nettogewinn erreichte 100 Millionen SEK, was einem Gewinn je Aktie von 0,74 SEK entspricht.
- None.
- None.
First quarter
- Sales of
SEK 842 (841) million, an increase of1% in local currencies and0% in SEK. The growth in local currencies excluding discontinued business was3% . - Sales per region, in local currencies was +
8% in EMEA, +14% excluding discontinued business, +9% inAmericas and -15% in APAC. - Sales per product groups, in local currencies excluding discontinued business was +
6% in Consumables, -5% in Technologies and +4% in Genetics. - Sales per product groups, in local currencies was +
3% in Consumables, -6% in Technologies and +1% in Genetics. - Gross margin increased to
57.4% (57.1). - Earnings before depreciation and amortisation (EBITDA) decreased to SEK 257 (272) million, giving an EBITDA margin of
30.6% (32.4), affected by foreign exchange impact of SEK -13 (1) million. - Operating cash flow amounted to SEK 69 million (198).
- Net income was
SEK 100 (115) million, resulting in earnings per share ofSEK 0.74 (0.85).
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 24-04-2025 08:00 CET.
For more information, please contact:
Helena Wennerström, acting CFO, phone: +4670 822 80 86
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Interim report Q1, 2025 |
View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ-interim-report-q1-2025-strong-performance-in-emea-302436973.html
SOURCE Vitrolife AB (publ)
FAQ
What was Vitrolife's (VTRLY) revenue growth in Q1 2025?
How did Vitrolife's regional sales perform in Q1 2025?
What was Vitrolife's EBITDA margin in Q1 2025?
How did Vitrolife's product segments perform in Q1 2025?
What were Vitrolife's earnings per share in Q1 2025?
